Business Wire - Biovail Reports 2003 Fourth Quarter and Full Year Financial Results
Monday, December 8th, 2008 Business Editors/Health/Medical Writers
TORONTO–(BUSINESS WIRE)–March 3, 2004
Biovail Corporation (NYSE:BVF) (TSX:BVF):
— Core Product sales revenue increases by 59%
— Core Product Revenue $172 million for 2003 versus $108 million
for 2002
— Biovail Pharmaceuticals Canada Product Revenue $85 million for
2003 versus $33 million for 2002
— Wellbutrin XL Revenue $65 million for 2003
…
